Heat Biologics Completes Patient Enrollment for Randomized Arms of Its Phase 2 HS-410 Bladder Cancer Trial
October 08, 2015 at 07:01 AM EDT
Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a clinical-stage cancer immunotherapy company, announced that it has completed enrollment ...
